PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.